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Abstract
In vivo, human immunodeficiency virus type 2 (HIV-2) infection reveals several unique characteristics when compared to HIV-1
infection, the most remarkable of which is the extraordinarily long asymptomatic period. Here we describe two HIV-2 primary isolates,
obtained from asymptomatic individuals, which do not infect any coreceptor-expressing cell lines tested. In those cells, we show that the
absence of replication is directly related to cell entry events. Furthermore, productive infection observed in peripheral blood mononuclear
cells (PBMC) was not inhibited by natural ligands and monoclonal antibodies directed to CCR5 and CXCR4. Finally, viral entry efficiency
and viral progeny production of these viruses are markedly impaired in PBMC, indicating a reduced replicative fitness of both viruses. In
conclusion, our data suggest that in some HIV-2 asymptomatic individuals, the circulating viruses are unable to use the major coreceptors
to infect PBMC. This fact should have important implications in HIV-2 pathogenesis and transmission.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Initial events in human immunodeficiency virus (HIV)
replication cycle include interactions between viral enve-
lope glycoproteins and cellular receptors that ultimately
lead to viral envelope and cell-membrane fusion. The entry
of HIV and simian immunodeficiency virus (SIV) into host
cells requires cell-surface CD4 as a primary receptor
(Dalgleish et al., 1984; Klatzmann et al., 1984). However,
human CD4 molecules themselves do not render cells sus-
ceptible to HIV type 1 (HIV-1) infection (Ashorn et al.,
1990; Chesebro et al., 1990; Clapham et al., 1991; Maddon
et al., 1986), suggesting that additional cell-surface compo-
nents are required for fusion and infection. These additional
components—coreceptors—were identified as members of
a family of seven-transmembrane, G-protein-coupled, re-
ceptors (GPCRs) (Alkhatib et al., 1996; Deng et al., 1996;
Feng et al., 1996). At the present, 19 of these GPCRs have
been shown to act in vitro as coreceptors for HIV-1, HIV
type 2 (HIV-2), and SIV: CCR1, CCR2b, CCR3, CCR4,
CCR5, CCR8, CCR9, CXCR2, CXCR4, CXCR5, CX3CR1,
GPR1, GPR15, STRL33, APJ, ChemR23, RDC1, BLTR,
and US28 (Broder and Jones-Trower, 1999; Simmons et al.,
2000).
The identification of chemokine receptors as HIV core-
ceptors had broadened the understanding on molecular
mechanisms underlying HIV-1 entry into target cells. Ac-
cording to the accepted model, HIV-1 entry begins with a
specific interaction between the virion heterodimeric Env
complex, formed by surface (SU) and transmembrane (TM)
glycoproteins, and two cellular proteins: CD4 and the co-
receptor. Binding of viral SU glycoprotein to CD4 appears
to cause structural changes in this glycoprotein that allow
exposure or formation of coreceptor-binding regions. Fur-
ther conformational changes induce the disclosure of fusion
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peptide in TM glycoprotein that ultimately leads to viral
envelope fusion with cellular membrane and the release of
viral nucleocapsid in cell cytoplasm (reviewed in Clapham
and McKnight, 2002; Reeves and Doms, 2002).
Despite the relative promiscuous chemokine receptor
usage in vitro by certain HIV-1 and particularly HIV-2
strains (Broder and Jones-Trower, 1999; Bron et al., 1997;
Guillon et al., 1998; McKnight et al., 1998; Morner et al.,
1999; Owen et al., 1998), CCR5 and CXCR4 are the major
coreceptors for HIV-1 and seem to be the only relevant in
HIV-1 pathogenesis (Simmons et al., 2000; Zhang et al.,
1998). Finding that humans homozygous for an inactive
mutant CCR5 allele (32ccr5) had greatly diminished risk
of infection with HIV-1 (Dean et al., 1996; Liu et al., 1996;
Mummidi et al., 1998; Samson et al., 1996) proved the
important role of CCR5 in HIV infection in vivo. Those rare
infection cases in 32ccr5 individuals (Balotta et al., 1997;
Biti et al., 1997; Michael et al., 1997, 1998; O’Brien et al.,
1997) appear to be associated with transmission of CXCR4-
dependent virus strains (Michael et al., 1998). These studies
also imply that CCR5 is the major coreceptor that mediates
person-to-person transmission of HIV-1. This notion is con-
sistent with the fact that CCR5-dependent (R5) strains are
predominant during early stages of HIV infection and only
in approximately 40% of late stage infected humans, viruses
arise that can use CXCR4 in addition to (R5X4 strains), or
sometimes instead of CCR5 (X4 strains) (Berger et al.,
1998, 1999; Simmons et al., 1996). The appearance of such
strains is associated with accelerated CD4 T cells loss and
disease progression (Bjorndal et al., 1997; Connor and Ho,
1994; Connor et al., 1997; Richman and Bozzette, 1994).
The great bulk of information regarding coreceptors us-
age and viral pathogenesis stems almost exclusively from
studies conducted with HIV-1 strains. However, several
data suggest that in general HIV-2 is less pathogenic than
HIV-1. In fact, despite the fact that both viruses are biolog-
ically and structurally similar, they differ in several impor-
tant aspects, as follows: transmission rates of HIV-2 are
much lower than those for HIV-1 (Adjorlolo-Johnson et al.,
1994; Andreasson et al., 1993; Kanki et al., 1994); epide-
miologic profile of HIV-2 and HIV-1 epidemics reflects
these differences in transmission rates: while HIV-1 has
spread virtually worldwide, HIV-2 is prevalent mainly in
West Africa (De Cock et al., 1993); although human infec-
tion with HIV-2 eventually leads to development of immu-
nological failure and AIDS, rates of disease progression and
mortality following HIV-2 infection are remarkably lower
than for HIV-1 (Jaffar et al., 1997; Marlink et al., 1994;
Poulsen et al., 1997; Whittle et al., 1994), suggesting that
HIV-2 has a significantly reduced pathogenicity in vivo
compared to HIV-1.
Major differences between HIV-1 and HIV-2 also in-
clude a different use of chemokine receptors as cofactors for
viral entry. As for HIV-1, all HIV-2 strains reported to date
use CCR5 and/or CXCR4 as major coreceptors to enter into
CD4 cells. However, many primary HIV-2 strains use a
broader range of coreceptors than HIV-1 and they can
exploit these coreceptors as efficiently as CCR5 or CXCR4
(Bron et al., 1997; Guillon et al., 1998; McKnight et al.,
1998). Some of these coreceptors are not, or very rarely,
used by HIV-1 (Broder and Jones-Trower, 1999). Addition-
ally, the ability of primary isolates to enter cells in a CD4-
independent way has been exclusively observed in HIV-2
(Reeves et al., 1999). Both features are related to oligomeric
structure of envelope glycoproteins (Reeves and Schulz,
1997), suggesting that this structure should be more flexible
in HIV-2 than in HIV-1.
With this work we intended to gain new insights on
HIV-2–coreceptor interactions using several primary HIV-2
isolates obtained from patients at different disease stages.
We found that coreceptor usage by two HIV-2 primary
isolates, obtained from asymptomatic patients, was unique
among divergent HIV-2 strains in that they are unable to
productively infect any cell line coexpressing CD4 and
chemokine receptors. Furthermore, we found that these
strains were resistant to CCR5 and CXCR4 targeted inhib-
itors, suggesting that they could enter cells independently of
CCR5 and CXCR4. From our results we hypothesize that a
natural HIV-2 infection in humans can occur by viral strains
that do not use CCR5 or CXCR4 as coreceptors to enter into
target cells.
Results
HIV-2MIC97 and HIV-2MJC97 do not infect GHOST or U87
cell lines
Coreceptor usage was analyzed by the ability to produc-
tively infect coreceptor-expressing cells and not only by
binding or fusion assays. This procedure has the advantage
of excluding possible ineffective interactions with corecep-
tors. These ineffective interactions could be sufficient for
viral binding and entry but insufficient to permit the com-
pletion of viral cycle due namely to the absence of activa-
tion signals mediated by “inappropriate” interaction with
chemokine receptors (Arthos et al., 2000; Baik et al., 1999;
Doranz et al., 1999; Liu et al., 2000). All HIV-2 isolates
were initially tested in GHOST cells expressing CD4 and
several chemokine receptors. From this group of isolates we
identified two, obtained from asymptomatic individuals
(HIV-2MIC97 and HIV-2MJC97), that were unable to produc-
tively infect any GHOST cell line, even those expressing
CCR5 or CXCR4 (Table 1). HIV-1 and HIV-2 strains with
known coreceptor usage were included to demonstrate the
appropriate coreceptor function of each GHOST cell line.
Replication of HIV-2MJC97 and HIV-2MIC97 was also ana-
lyzed in peripheral blood mononuclear cells (PBMC), CD8-
depleted PBMC, and MDM. Productive infection was ob-
served in all cases by RT activity in culture supernatants
(Table 1). So apparently, HIV-2MIC97 and HIV-2MJC97
could replicate normally in peripheral blood CD4 cells but
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are unable to productively infect any GHOST cell lines.
Since GHOST cells carry an LTR-GFP reporter gene, which
is switched when infected, we analyzed GFP expression in
GHOST-infected cells by fluorescent microscopy to confirm
our results regarding productive infection. This analysis was
performed in triplicate at days 1, 2, 3, and 7 after infection
and results, shown in Table 1, confirmed that all GHOST
cell lines tested were resistant to HIV-2MIC97 and HIV-
2MJC97 infection. We further address this issue using human
glioma cell-line U87. Therefore we exposed U87 CD4
cells expressing several chemokine receptors to this group
of HIV-2 primary isolates. Viral replication was negative
for HIV-2MIC97 and HIV-2MJC97 in all cell lines as assessed
by RT activity in culture supernatants (Table 1) and viral
protein production by IFA (data not shown).
In addition, and despite the fact we are analyzing a
limited number of samples, we attempted to establish a
correlation between clinical stage and coreceptor usage.
From this analysis (Table 1) it is worth noting that the
acquisition of CXCR4 usage by HIV-2 is associated, as in
HIV-1, with more advanced stages of infection (Bjorndal et
al., 1997; Scarlatti et al., 1997). Reciprocally, the exclusive
use of CCR5 by HIV-2 strains is predominantly observed in
asymptomatic or early symptomatic stages (HIV-2MS, HIV-
2MMS, and HIV-2ALI), suggesting that during symptomatic
stages, viral variants with a broader coreceptor usage phe-
notype (including CCR5, CXCR4, and others) emerge,
which in some cases could ultimately evolve to a viral
population exclusively using CXCR4.
HIV-2MIC97 and HIV-2MJC97 do not enter into coreceptor
expressing cells
We wanted to verify if viral entry step was determinant
in abortive infections observed in GHOST cell lines, thus
excluding a possible contribution of postentry events. For
that purpose we measured viral core protein amounts in
cytosolic fractions of coreceptor-expressing GHOST-CD4
cells exposed to several HIV-2 and HIV-1 isolates. The
detection of p24 viral core protein in cytosolic fractions of
cells exposed to HIV-1 is correlated with true productive
infection (Marechal et al., 1998) and allows concluding
about efficient viral entry into cells. This correlation was
also observed in HIV-2 (Fig. 1) as demonstrated when
primary strains (HIV-2ALI and HIV-2TER) with known co-
receptor usage (Reeves et al., 1999; this report) were used,
which also stands for the functional expression of corecep-
tors in GHOST cell lines. Furthermore and more important,
our results demonstrate that cytosolic fractions of GHOST
cells exposed to 400 ng of p27Ag of both HIV-2MIC97 and
HIV-2MJC97 show levels of viral core protein virtually equal
to mock-infected cultures. This implies that both viruses are
Table 1
Tropism of several HIV-2 primary isolates for primary cells, GHOST, and U87 cell linesa
Viruses
MIC97 MJC97 MMS MS ALI MLC ETP JAU TER SAB MIL
Clinical stageb Asympt
(A2)
Asympt
(A2)
Asympt
(A2)
Asympt
(A2)
Sympt
(B3)
Sympt
(B3)
Sympt
(C3)
Sympt
(C3)
Sympt
(C3)
Sympt
(C3)
Sympt
(C3)
Primary cells
PBMC           
CD8-dep           
MDM   ND ND  ND ND ND ND ND ND
GHOST CD4 expressingc
CCR1 / /   /    / / 
CCR2b / /   /    / / 
CCR3 / /   /    / / 
CCR5 / /   /    / / 
CXCR4 / /   /    / / 
GPR15 / /   /    / / 
STRL33 / /   /    / / 
GHOST CD4           
U87 CD4 expressing
CCR1           
CCR2b           
CCR3           
CCR5           
CXCR4           
U87 CD4           
Note. Abbreviations: Asympt, asymptomatic; Sympt, symptomatic; CD8-dep, CD8-depleted PBMC; ND, not done.
a Viral replication was assessed by RT activity in culture supernatants.
b CDC classification of clinical stage is referred in parentheses.
c In addition to viral replication detected by RT activity, in GHOST cell lines viral replication of some viruses (MIC97, MJC97, ALI, TER and SAB) was
also monitored by GFP expression of LTR-GFP reporter gene by fluorescent microscopy. In those cases both results are shown (RT activity/GFP expression).
138 J.M. Azevedo-Pereira et al. / Virology 313 (2003) 136–146
unable to enter into GHOST cell lines even though they
enter into CD4 PBMCs. Similar results were obtained
when 800 ng of p27Ag of each virus was used in GHOST
cell lines (data not shown).
Of note, although HIV-2MIC97 and HIV-2MJC97 are both
able to enter into CD4 PBMCs, they reveal a marked
lower level of viral antigen in cytosolic fraction when com-
pared with R5 (HIV-2ALI and HIV-1JRCSF) or R5X4 strains
(HIV-2TER) included (Fig. 1). For HIV-2MIC97 the differ-
ences in viral entry efficiency compared to the others strains
ranged from 49.2 to 63.7% and for HIV-2MIC97 those dif-
ferences ranged from 38 to 55.8%. Taking this significant
impairment in the efficiency of viral entry observed in both
HIV-2MIC97 and HIV-2MJC97, we wanted to verify if this
lower infectivity could be mirrored by the kinetics of rep-
lication of these viruses. As expected, both viruses showed
a lower and slower replication in PHA-activated PBMC
(Fig. 2). Notably, viral replication of HIV-2MIC97 and HIV-
2MJC97 was only observed when the amount of input viruses
was equal or higher than 10 ng of RT activity; below that,
viral progeny production was undetectable (data not
shown), strongly indicating a severe lack of replicative
fitness in vitro, apparently due to a deficient interaction with
cellular receptors as suggested by viral entry data.
HIV-2MIC97 and HIV-2MJC97 are resistant to CCR5 and
CXCR4 targeted inhibitors
Since HIV-2MIC97 and HIV-2MJC97 infected productively
PHA-stimulated PBMC, we used this cell system to inves-
tigate if CCR5 and CXCR4 were utilized by these strains to
enter in PBMC. We wanted to test the ability of CCR5- and
CXCR4-targeted molecules to inhibit productive infection
of these two viruses. Accordingly, we infected CD8-de-
pleted PBMC in the presence of several concentrations of
RANTES and SDF-1, natural ligands of CCR5 and
CXCR4, respectively, and MAbs 2D7 and 12G5, specific
for CCR5 and CXCR4, respectively (Bleul et al., 1996;
Cocchi et al., 1995; McKnight et al., 1997; Oberlin et al.,
1996; Wu et al., 1997). The presence of these inhibitors did
not affect the replication of HIV-2MIC97, even at highest
concentrations (Fig. 3). Viral replication in inhibitor-treated
PBMC was equal, and in some cases higher, than that
Fig. 1. Detection of p27 protein in cytosolic fraction obtained from cells (4 106) exposed to different HIV-2 isolates (400 ng of p27 for each virus). The background
obtained in each cell line was subtracted from the final result. The data are expressed as means of at least three independent experiments  standard deviations.
Fig. 2. Growth of HIV-2MIC97 and HIV-2MJC97 in PBMC. PHA-activated
PBMC were exposed to 10 ng of RT activity of each virus and viral
progeny production was followed during a 21-day period.
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observed in nontreated PBMC. We also noticed that HIV-
2MJC97 was partially inhibited by extremely high concentra-
tion (50 g/ml) of MAb 2D7 (Fig. 3), although the speci-
ficity of 2D7 to CCR5 at such concentrations may be
affected. Viral strains used as controls were inhibited either
by RANTES and 2D7 (HIV-2ALI and HIV-1JRCSF) or by
SDF-1 and 12G5 (HIV-2SAB), in agreement with de-
scribed coreceptor usage (Broder and Jones-Trower, 1999;
Reeves et al., 1999; this report). However the presence of
saturating concentrations (10 g/106 cells) of monoclonal
antibody SIM.4, directed to CD4, inhibit more than 90% of
HIV-2MIC97 and HIV-2MJC97 replication (data not shown),
indicating that viral entry is mediated by CD4. In conclu-
sion, inhibition experiments with receptor ligands confirmed
that PBMC infection by HIV-2MIC97 and HIV-2MJC97 was not
reliant on functional availability of either CCR5 or CXCR4 but
is strictly dependent on the presence of CD4.
Detection of 32ccr5 deletion and ccr5 promoter
polymorphism
The rationale for these experiments was to exclude the
existence of any mutation in ccr5 locus that could be di-
rectly responsible for the absence or diminished expression
of CCR5 receptor in MIC or MJC patients PBMC. These
mutations, if present, could account for an in vivo selection
of a non-CCR5 viral population due to a particular host
environment. With this aim we investigated the presence of
a 32-bp deletion in ccr5 gene (32ccr5) responsible for the
absence or greatly diminished expression of CCR5 corecep-
tor (Dean et al., 1996; Liu et al., 1996; Samson et al., 1996).
As expected for African patients (as was the case of MIC
and MJC), none of the individuals are homozygote or het-
erozygote for 32ccr5 (Fig. 4A), in agreement with the
restricted distribution of this mutation in Caucasians (Mar-
tinson et al., 1997).
Besides 32ccr5 deletion, other polymorphisms in the
ccr5 gene have been shown to influence CCR5 expression
and HIV susceptibility. Two of them are located in the
promoter region and have been described as G/A 59029 and
C/T59353 (McDermott et al., 1998). The latter is largely
confined to people of African descendent and it seems to
increase the likelihood of infants acquiring HIV infection
from their mothers (Kostrikis et al., 1999). The results,
shown in Figs. 4B and C, indicate that MIC is heterozygote
for both polymorphisms (CT59353 and GA59029), while
MJC is homozygote (TT59353 and GG59029). However,
both genetic polymorphisms could not account per se to a
diminished expression of CCR5 coreceptor and thus to a
selection of CCR5-independent population. According to
these results, we may conclude that the presence of CCR5-
independent variants in MIC and MJC patients could not be
attributable to a selective pressure due to host genetic char-
acteristics related to CCR5 coreceptor expression.
Fig. 3. Inhibition of replication of several primary HIV-2 isolates by monoclonal antibodies 2D7 (A) and 12G5 (C), and by natural ligands RANTES (B) and
SDF-1 (D) directed to CCR5 and CXCR4, respectively. Percentage of residual infection was calculated considering as 100% the RT value obtained in
control cultures without inhibitors. The data are expressed as means of at least three different experiments.
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Discussion
Although some HIV-2 primary isolates and a small num-
ber of T cell adapted HIV-1 strains seem able to infect cells
directly via CCR5 or CXCR4, without any requirement for
CD4 (Dumonceaux et al., 1998; Kolchinsky et al., 1999;
Reeves et al., 1999), the major pathway for HIV entry
requires the interaction with CD4 and CCR5 or CXCR4
(Clapham and McKnight, 2002; Reeves and Doms, 2002).
In this work we demonstrate that two HIV-2 primary strains
(HIV-2MIC97 and HIV-2MJC97), obtained from asymptom-
atic individuals, are unable to productively infect a panel of
GHOST and U87 cell lines coexpressing CD4 and chemo-
kine receptors CCR1, CCR2, CCR3, CCR5, CXCR4,
STRL33, and GPR15, even though these cells express re-
ceptors functional for other primary HIV-2 isolates. We also
demonstrate that the inability to perform a productive in-
fection is related to the inability to enter into these cells.
This excludes a possible postentry blockage due to delivery
of viral core into some inappropriate cellular compartment,
as referred to other HIV-2 strains (McKnight et al., 2001)
or, alternatively, due to inadequate interactions with cellular
receptors that may lead to ineffective signal transduction
and hence, to suboptimal activation of intracellular factors
indispensable to conclude replication cycle (Chackerian et
al., 1997; Weissman et al., 1997).
Furthermore, the presence of CCR5- and CXCR4-tar-
geted inhibitors did not affect replication of one of those
HIV-2 isolates (HIV-2MIC97) in CD8-depleted PBMC and
only partially inhibited HIV-2MJC97 replication at extremely
high concentrations of MAb 2D7 (50 g/ml). These results,
together with the inability to productively infect GHOST
and U87 cell lines, strongly suggest that HIV-2MIC97 and
HIV-2MJC97 are able to use a distinct coreceptor molecule to
enter into PHA-stimulated PBMC. This or these mole-
cule(s) should be present in activated PBMC but absent in
GHOST or U87 cell lines.
Alternatively, HIV-2MIC97 and HIV-2MJC97 may use
CCR5 or CXCR4 present in PBMC in a manner that is
insensitive to RANTES, SDF-1, 2D7, or 12G5. A situation
similar to that described for the emergence of escape mu-
tants to MAb 2D7 (Aarons et al., 2001), where viral strains
continue to use CCR5 but in a manner independent of
second extracellular loop (ECL-2) interaction, which con-
stitutes the target for MAb 2D7 (Wu et al., 1997). However,
this hypothesis, although consistent with the observation
that high concentrations of 2D7 inhibited HIV-2MJC97 rep-
lication, has two important flaws and incompatibilities with
our results. The first one is that HIV-2MJC97 and HIV-2MIC97
are completely naı¨ve to 2D7 as they were isolated and
propagated in the absence of any chemokine or MAb. Sec-
ond, this hypothesis is not sufficient to explain non-usage of
coreceptors present in GHOST or U87 cell lines, except if
we assume that these coreceptors could be expressed in
some isoforms that are inadequate to mediate viral entry by
HIV-2MIC97 and HIV-2MJC97. It has been suggested that
CXCR4 can exist in different isoforms on different cell
types (McKnight et al., 1997). Also CCR5 could exist in
different entry-competent states that are cell-type and virus-
type dependent (Olson et al., 1999). In any case we must
assume that this incapability was highly specific to these
two viruses, a highly improbable requirement.
Despite heterogeneity in HIV coreceptor usage, particu-
larly in some primary HIV-2 isolates (Bron et al., 1997;
McKnight et al., 1998), CCR5 and, although less frequently,
CXCR4 are the major chemokine receptors needed, in ad-
dition to CD4, for HIV fusion with the cell membrane. All
HIV-1 and HIV-2 strains reported so far use either CCR5 or
CXCR4 or both as coreceptors to enter into CD4-positive
cells (Broder and Jones-Trower, 1999). Nevertheless, some
studies had suggested, although quite concealed, the exis-
tence of some HIV-2 strains that used CCR5 or CXCR4 less
efficiently. In one of these studies (Zhang et al., 2000), an
HIV-2 strain was described in which replication in PBMC
was only inhibited by high concentrations of AMD3100, a
potent CXCR4 inhibitor (Donzella et al., 1998), and totally
insensitive to SDF-1, TAK-779, and AOP-RANTES. Yet
this strain replicates quite efficiently in GHOST cells ex-
pressing CXCR4. A more interesting strain was reported by
Sol and co-workers (Sol et al., 1997). This strain (HIV-2D)
is unable to use CCR5, CXCR4, or CCR3 coreceptors
expressed in U87MG-CD4 and HeLa-CD4 cell lines, sug-
gesting the use of alternative coreceptors. However, the
usage of other coreceptors was not investigated nor did the
authors examine the contribution of viral entry step in the
abortive infections observed in coreceptor-expressing cells.
Fig. 4. Study of ccr5 locus. (A) Analysis of 32ccr5 deletion in individuals infected with HIV-2MIC97 (Lane 1), HIV-2MJC97 (Lane 2), and from a wild-type
(wt) ccr5 individual (Lane 3). Analysis of ccr5 promoter polymorphism C/T 59353 (B) and G/A 59029 (C) in individuals infected with HIV-2MIC97 (Lane
1) and HIV-2MJC97 (Lane 2) and in wt ccr5 individual used in (A).
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Nevertheless it is important to note that this primary isolate,
similarly to HIV-2MIC97 and HIV-2MJC97, was also obtained
from an asymptomatic individual.
Also in HIV-1, a truly remarkable finding reported by
Saha et al. (2001) suggests the emergence, in late stages
patients, of HIV-1 variants that, although requiring the pres-
ence of CXCR4 when infecting CD4-positive cells, they are
able to infect cells through interaction with CD8, in the
absence of either CCR5 or CXCR4.
In the SIV model, several studies suggested a great
complexity in coreceptor usage (Edinger et al., 1998; Farzan
et al., 1997; Samson et al., 1998; Shimizu et al., 2000; Yi et
al., 2001; Zhang et al., 2000). In this model, where CXCR4
usage is rare (Schols and De Clercq, 1998), some strains
have been described that do not use CCR5 to infect primary
lymphocytes (Chen et al., 1998). Noteworthy, these strains
were isolated from animals with a 24-bp deletion in ccr5
gene (24ccr5), similar to 32ccr5 in humans, and are able
to infect cells expressing CCR2, STRL33, V28, and US28
(Zhang et al., 2000).
Taken together, these observations emphasize the out-
standing plasticity of HIV and SIV envelope proteins and
raise two important questions. One reminds us that HIV,
similar to SIV, is highly prone to mutations and has an
enormous capacity to adapt to host-driven pressures. Based
on this, we investigated the possible presence of genetic
determinants in MIC and MJC patients to exclude in vivo
selection of CCR5-independent variants. The other impor-
tant and fundamental issue is that a persistent lentiviral
infection could be established without the strict need of
CCR5 coreceptor use, a need that seems to be a hallmark in
early stages of HIV-1 infection as shown by several evi-
dences (Dean et al., 1996; Liu et al., 1996; Long et al., 2002;
Salvatori and Scarlatti 2001; Samson et al., 1996). Further-
more, CCR5 usage is maintained throughout the entire dis-
ease course and, in 50% of AIDS patients, R5 strains are the
only strains that are recovered (Bjorndal et al., 1997; Con-
nor et al., 1997). Most remarkably, HIV-1 only needs to
change one amino acid in gp120 V3 loop to switch viral
coreceptor usage (Briggs et al., 2000; Hu et al., 2000;
Shimizu et al., 1999; Verrier et al., 1999). For a virus like
HIV-1 with such a high rate of genetic drift and rapid
turnover in vivo, it seems to be quite bizarre that even after
several years of chronic infection, a viral population still
maintains CCR5 as coreceptor. What makes CCR5 usage so
important for HIV-1 at least in early stages of infection?
One possible explanation should be related to CCR5 expres-
sion patterns in different lymphocytes subsets. CCR5 ex-
pression is higher in memory T-CD4 lymphocytes
(CD45RO) and lower in naı¨ve T-CD4 lymphocytes
(CD45RA) (Bleul et al., 1997). CD45RO lymphocytes
are also highly permissive to HIV-1 replication (Roederer et
al., 1997; Spina et al., 1997). Additionally, several in vitro
studies have suggested that activation state of target cell is
an important factor to establish a productive infection by
HIV-1 (Ostrowski et al., 1998; Stevenson et al., 1990).
Notably, HIV-1 entry into CD45RA lymphocytes requires
cellular activation in a time-dependent manner after viral
entry, otherwise an abortive infection is observed (Woods et
al., 1997). So, apparently CCR5 usage makes HIV-1 able to
infect stimulated, full-permissive cells and could be seen as
an evolutionary advantage probably acquired by HIV-1 in
its “humanization” process. Additionally, HIV-1 R5 vari-
ants may be able to more easily escape to neutralization by
HIV-1-specific antibodies.
The most prudent conclusion from results presented here
is that a viral population, that does not use CCR5 or CXCR4
to enter into target cells, is present in some asymptomatic
patients infected with HIV-2. The isolation of these strains
from asymptomatic individuals raises the possibility that, in
vivo, CCR5 usage is acquired during HIV-2 evolution from
an initial population of CCR5- and CXCR4-independent
viruses. If a more exhaustive survey of HIV-2 strains iso-
lated from asymptomatic individuals confirms our present
data, this fact implies that, during a variable period of time,
a less fitted viral population exists that needs to evolve to
exploit CCR5 coreceptor and consequently become more
virulent. Consequently, we suggest that the existence of a
CCR5-independent population in asymptomatic HIV-2 pa-
tients could be related to the characteristically longer
asymptomatic stage observed in HIV-2 infection and ulti-
mately could help explain some of the differences in patho-
genic potential between HIV-2 and HIV-1, particularly in
early stage patients.
Materials and methods
Cells
PBMCs from patients and donors were stimulated with
phytohemagglutinin (PHA) and cultured as described
(Reeves et al., 1999). PBMC used in all experiments re-
ported here were obtained from the same donors to avoid
interindividual variations in HIV infection susceptibility.
Human osteosarcoma cell line GHOST and GHOST-de-
rived cell lines expressing coreceptors and human glioma
cell line U87 and U87-derived cell lines expressing core-
ceptors were cultured as described (Reeves et al., 1999).
CD8-depleted PBMCs were obtained from PBMCs after
removal of CD8 cells, using magnetic beads coated with
anti-CD8 antibody (Dynal). CD4 PBMCs were obtained
from total PBMCs by positive selection of CD4 cells using
magnetic beads coated with anti-CD4 antibody (Dynal).
Monocyte-derived macrophages (MDM) were isolated and
cultured as described (Gartner et al., 1986).
HIV-2 viruses
HIV-2MIC97 and HIV-2MJC97 as well as all primary
HIV-2 isolates were obtained from PBMC of infected pa-
tients by cocultivation with PHA-stimulated PBMC from
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uninfected individuals. HIV-1JRCSF is a CCR5 using HIV-1
strain (Simmons et al., 1996). Viral stocks were established
from low-passaged supernatants of infected PBMC.
Infectivity assays
GHOST and U87 cell lines expressing chemokine receptors
were seeded into 24-well plates on the day prior to infection, at
1.5 105 cells/well. To assess chemokine usage, each cell line
was inoculated with equal amounts of each virus (100 TCID50
in a final volume of 100 l/well) and incubated for 3 h/37°C in
the presence of 3 g/ml of Polybrene. Cells were then washed
and cultured in appropriate culture medium (500 l/well).
Viral replication was monitored by reverse transcriptase (RT)
activity by an enzyme-linked immunosorbent assay (Lenti-RT
kit, Cavidi) in culture supernatants every 3 days. For viral
replication kinetics, PHA-activated PBMC were incubated
with equal amounts of each virus (10 ng of RT) for 2 h/37°C
in the presence of Polybrene (3 g/ml). Supernatants, sampled
over 21 days, were assayed for RT activity as described above.
Additionally, since GHOST cell lines carry an LTR-GFP re-
porter gene, which is switched on when cells are infected, we
used GFP expression to detect infected cells. GHOST cells
were treated and exposed to viruses as described above and
analyzed for GFP expression. This analysis was performed in
three independent experiments at days 1, 2, 3, and 7 after
infection by fluorescent microscopy using mock-infected cells
to exclude background fluorescence of each GHOST cell line.
The presence of fluorescent cells on any of these days was
considered as a positive result.
Inhibition of replication in PBMC
These assays were done using CD8-depleted PBMCs.
Cells were screened for CCR5-defective alleles and only
cells from wild-type donors were used. After PHA and IL-2
stimulation, cells were incubated with different concentra-
tions of each inhibitor tested [RANTES, monoclonal anti-
body (MAb) 2D7 (Pharmingen), SDF-1 (R&D Systems),
MAb 12G5, and SIM.4] for 1 h/37°C. Viruses were then
added as described in infectivity assays and incubated for
4 h in inhibitor-containing medium. After washing, cells
were cultured in medium containing the desired concentra-
tion of each inhibitor. Virus production (assessed by RT
activity) in the absence of inhibitors was designated as
100%, and the ratios of RT activity in inhibitor-containing
cultures were calculated relative to this.
ccr5 locus analysis
Genomic DNA was isolated from an individual of known
CCR5 genotype (wild-type ccr5/ccr5) and from MIC and
MJC patients by a commercially available kit (Gentra). For
32ccr5 genotyping, approximately 200 ng of each DNA
was amplified by PCR in a 50 l reaction using 2.5 U of
Taq/Pwo DNA polymerases mix (Expand Long Template
PCR System, Roche), 2.25 mM MgCl2, 500 mM of each
dNTP, and 300 nM of each primer (CCR5-F: 5-CCTG-
GCTGTCGTCCATGCTG-3 and CCR5-R: 5-AGCCAT-
GTGCACAACTCT-3). Amplification was performed with
35 cycles of 30 s at 94°C, 45 s at 60°C, and 90 s at 68°C,
preceded by 94°C for 2 min and followed by 68°C for 10
min. Amplification products were resolved by 2% agarose
gel electrophoresis and stained with ethidium bromide. The
presence of G/A 59029 and C/T 59353 CCR5 promoter
polymorphism was investigated using the protocol de-
scribed by Clegg et al. (2000).
Detection of viral antigen in cellular cytosolic fraction
Viral antigen was detected in cytosolic fraction as de-
scribed by Mare´chal et al. (1998). Briefly, GHOST-CD4
cells expressing several coreceptors and PHA-stimulated
CD4 PBMC were washed twice with cold phosphate-
buffered saline (PBS) and maintained in cold (0°C) DMEM
or RPMI 1640 medium containing DEAE-dextran (20 g/
ml) and 20 mM HEPES. After 5 min on ice, cells (4  106
cells in each 35-mm -well) were incubated with equal
amounts of each virus, measured by p27 Ag (for HIV-2
strains) or p24 Ag (for HIV-1JRCSF) concentration. After 60
min at 4°C with frequent agitation, cells were washed three
times with cold PBS (4°C) and either immediately treated
with Pronase or incubated at 37°C for 1 h before Pronase
treatment. For Pronase treatment, cells were resuspended in
1 ml of appropriate medium (4°C) containing 20 mM
HEPES and 5 mg/ml Pronase during 10 min at 4°C. Cells
were washed once with cold culture media (4°C) supple-
mented with 10% (v/v) FCS and three times with cold PBS
(4°C) to eliminate Pronase. After washing, cells were incu-
bated with swelling buffer (10 mM Tris–HCl pH 8, 10 mM
KCl, 1 mM EDTA) for 1 min at 4°C and lysed by Dounce
homogenization. Nuclei and cell debris were pelleted by
centrifugation (3000 rpm for 3 min). Cleared supernatants
were then ultracentrifuged (60,000 rpm for 10 min at 4°C)
in a Beckman TL100 centrifuge. The supernatant, corre-
sponding to cytosolic fraction, was adjusted to 0.5% Triton
X-100. Concentrations of HIV-2 or HIV-1 (for HIV-1JRCSF
strain used) core antigen were measured using a p27 (SIV-
core antigen kit; Coulter) or a p24 (Vironostika HIV-1
Antigen; Organon Teknika) immunoassay according to
manufacturer’s instructions. For each cell line and virus
examined, p27 or p24 background level, obtained from cells
immediately treated with Pronase after absorption at 4°C,
was subtracted from the amount detected in conditions al-
lowing virus internalization.
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